Literature DB >> 23835632

Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1.

Ana Treviño1, Jose L Vicario, Mariola Lopez, Patricia Parra, Rafael Benito, Raul Ortiz de Lejarazu, Jose M Ramos, Jorge Del Romero, Carmen de Mendoza, Vincent Soriano.   

Abstract

HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) develops in less than 5 % of HTLV-1 carriers. It is unclear which factors trigger the development of disease. The aim of this study was to explore the influence of HLA alleles on the development of HAM/TSP. A total of 40 HTLV-1-infected individuals belonging to the Spanish HTLV-1 cohort were examined. HTLV-1 proviral load was measured by real-time polymerase chain reaction. HLA class I (A, B, C) and class II (DRB1, DQB1) alleles were genotyped using the bead array technology. Median HTLV-1 proviral load in 12 HAM/TSP patients was greater than in 28 asymptomatic carriers (637 vs. 71 copies per 10(4) peripheral blood mononuclear cells; p = 0.006). Moreover, HAM/TSP was significantly associated with HLA-B 07 and HLA-DRB1 01:01 (p = 0.039). Interestingly, individuals with these HLA alleles had greater HTLV-1 proviral load than asymptomatic carriers (p = 0.036). In summary, HLA testing should be considered in asymptomatic HTLV-1 individuals and close monitoring of HTLV-1 proviral load along with periodic neurological evaluations should be prioritized in HLA-DRB1 01:01 and HLA-B 07 carriers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23835632     DOI: 10.1007/s00415-013-7014-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

2.  HLA class I alleles in HTLV-1-associated myelopathy and asymptomatic carriers from the Brazilian cohort GIPH.

Authors:  B C Catalan-Soares; Anna Bárbara F Carneiro-Proietti; F G Da Fonseca; R Correa-Oliveira; D Peralva-Lima; R Portela; J G Ribas; D U Gonçalves; F A Proietti
Journal:  Med Microbiol Immunol       Date:  2008-06-03       Impact factor: 3.402

3.  Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.

Authors:  Masako Iwanaga; Toshiki Watanabe; Atae Utsunomiya; Akihiko Okayama; Kaoru Uchimaru; Ki-Ryang Koh; Masao Ogata; Hiroshi Kikuchi; Yasuko Sagara; Kimiharu Uozumi; Manabu Mochizuki; Kunihiro Tsukasaki; Yoshio Saburi; Masaomi Yamamura; Junji Tanaka; Yukiyoshi Moriuchi; Shigeo Hino; Shimeru Kamihira; Kazunari Yamaguchi
Journal:  Blood       Date:  2010-05-06       Impact factor: 22.113

4.  Preferential recognition of synthetic peptides from HTLV-I gp21 envelope protein by HLA-DRB1 alleles associated with HAM/TSP (HTLV-I-associated myelopathy/tropical spastic paraparesis).

Authors:  Y Yamano; B Kitze; S Yashiki; K Usuku; T Fujiyoshi; T Kaminagayoshi; K Unoki; S Izumo; M Osame; S Sonoda
Journal:  J Neuroimmunol       Date:  1997-06       Impact factor: 3.478

5.  HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.

Authors:  K J Jeffery; K Usuku; S E Hall; W Matsumoto; G P Taylor; J Procter; M Bunce; G S Ogg; K I Welsh; J N Weber; A L Lloyd; M A Nowak; M Nagai; D Kodama; S Izumo; M Osame; C R Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad.

Authors:  E M Maloney; F R Cleghorn; O S Morgan; P Rodgers-Johnson; B Cranston; N Jack; W A Blattner; C Bartholomew; A Manns
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-02-01

7.  Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton.

Authors:  Tadahiko Igakura; Jane C Stinchcombe; Peter K C Goon; Graham P Taylor; Jonathan N Weber; Gillian M Griffiths; Yuetsu Tanaka; Mitsuhiro Osame; Charles R M Bangham
Journal:  Science       Date:  2003-02-13       Impact factor: 47.728

Review 8.  An HTLV-I vaccine: why, how, for whom?

Authors:  G de Thé; R Bomford
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

9.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations.

Authors:  Faviel F Gonzalez-Galarza; Stephen Christmas; Derek Middleton; Andrew R Jones
Journal:  Nucleic Acids Res       Date:  2010-11-09       Impact factor: 16.971

View more
  8 in total

Review 1.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

2.  Cytokine profile and proviral load among Japanese immigrants and non-Japanese infected with HTLV-1 in a non-endemic area of Brazil.

Authors:  João Américo Domingos; Luana Silva Soares; Larissa M Bandeira; Camila Mareti Bonin; Ana C P Vicente; Louise Zanella; Marco Antonio Moreira Puga; Inês Aparecida Tozetti; Ana Rita Coimbra Motta-Castro; Rivaldo Venâncio da Cunha
Journal:  PLoS One       Date:  2017-04-04       Impact factor: 3.240

3.  HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina.

Authors:  Paula Benencio; Sindy A Fraile Gonzalez; Nicolás Ducasa; Kimberly Page; Carolina A Berini; Mirna M Biglione
Journal:  Retrovirology       Date:  2020-09-03       Impact factor: 4.602

4.  Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population.

Authors:  Marina Penova; Shuji Kawaguchi; Jun-Ichirou Yasunaga; Takahisa Kawaguchi; Tomoo Sato; Meiko Takahashi; Masakazu Shimizu; Mineki Saito; Kunihiro Tsukasaki; Masanori Nakagawa; Norihiro Takenouchi; Hideo Hara; Eiji Matsuura; Satoshi Nozuma; Hiroshi Takashima; Shuji Izumo; Toshiki Watanabe; Kaoru Uchimaru; Masako Iwanaga; Atae Utsunomiya; Yasuharu Tabara; Richard Paul; Yoshihisa Yamano; Masao Matsuoka; Fumihiko Matsuda
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 12.779

5.  HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Is Not Associated with SNP rs12979860 of the IL-28B Gene.

Authors:  Antonio C R Vallinoto; Bárbara Brasil Santana; Keyla S G Sá; Tuane C S Ferreira; Rita Catarina M Sousa; Vânia N Azevedo; Rosimar N M Feitosa; Luiz Fernando A Machado; Marluísa O G Ishak; Ricardo Ishak
Journal:  Mediators Inflamm       Date:  2015-11-01       Impact factor: 4.711

Review 6.  Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections.

Authors:  Tatiane Assone; Arthur Paiva; Luiz Augusto M Fonseca; Jorge Casseb
Journal:  Viruses       Date:  2016-02-03       Impact factor: 5.048

Review 7.  Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons.

Authors:  Antonio Carlos Rosário Vallinoto; Izaura Cayres-Vallinoto; Maria Alice Freitas Queiroz; Marluísa de Oliveira Guimarães Ishak; Ricardo Ishak
Journal:  Viruses       Date:  2019-10-23       Impact factor: 5.048

Review 8.  Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Retrovirology       Date:  2019-11-29       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.